Lower respiratory tract infection future or investigational therapies

Revision as of 22:33, 29 July 2020 by WikiBot (talk | contribs) (Bot: Removing from Primary care)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Lower respiratory tract infection Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lower respiratory tract infection from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lower respiratory tract infection future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lower respiratory tract infection future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lower respiratory tract infection future or investigational therapies

CDC on Lower respiratory tract infection future or investigational therapies

Lower respiratory tract infection future or investigational therapies in the news

Blogs on Lower respiratory tract infection future or investigational therapies

Directions to Hospitals Treating Lower respiratory tract infection

Risk calculators and risk factors for Lower respiratory tract infection future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Future or Investigational Therapies

It is likely that the future treatment of lower respiratory tract infections will consist of new antibiotics aimed at facing the problems associated with the constant emergence of antibiotic resistance. With resistance evolving so rapidly future treatments may include the use of vaccines to prevent these infections. Although a Cochrane systematic review of a polysaccharide pneumococcal vaccine showed that it didn’t reduce pneumonia or related deaths in adults, but it was able to reduce incidence of more specific outcomes such as pneumococcal disease in the elderly. So it is hoped with further developments these will become more effective against pneumonia.

Vaccination of patients with AECB in the autumn months is thought to have a positive effect in reducing the severity and number of exacerbations over winter. The oral vaccine described in this review was able to decrease the carriage or non- typeable Haemophilus influenzae that is a common cause of exacerbations to chronic bronchitis. With good planing and further research these types of vaccines may reduce the burden associated with lower respiratory diseases.

There are few treatments available for viral forms of bronchitis and pneumonia. Respiratory syncytial virus (RSV), the main cause of these in children, could be potentially treated using a new monoclonal antibody (mAb) Motavizumab. In animal trials it reduced antibody titres 100 times lower than the only drug currently available to treat the condition. This holds great promise for future treatments of LRTI.

References


Template:WikiDoc Sources